Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · Real-Time Price · USD
0.630
-0.014 (-2.24%)
At close: Dec 5, 2025, 4:00 PM EST
0.603
-0.027 (-4.30%)
After-hours: Dec 5, 2025, 7:56 PM EST
Virax Biolabs Group Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 |
| Revenue | 0 | 0.01 | 0.16 | 0.01 | - | 0.12 | Upgrade
|
| Revenue Growth (YoY) | -96.48% | -95.95% | 1727.11% | - | - | 23.97% | Upgrade
|
| Cost of Revenue | 0.05 | 0.06 | 0.11 | 0.01 | - | 0.13 | Upgrade
|
| Gross Profit | -0.05 | -0.05 | 0.05 | -0 | - | -0.01 | Upgrade
|
| Selling, General & Admin | 3.39 | 4.33 | 4.59 | 3.55 | 1.3 | 0.51 | Upgrade
|
| Research & Development | 2.43 | 1.78 | 1.56 | 2.18 | 0.43 | 0.12 | Upgrade
|
| Operating Expenses | 5.82 | 6.11 | 6.16 | 5.73 | 1.73 | 0.64 | Upgrade
|
| Operating Income | -5.87 | -6.16 | -6.11 | -5.73 | -1.73 | -0.64 | Upgrade
|
| Interest Expense | -0.06 | -0.06 | -0.03 | -0.02 | -0.02 | -0.03 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.01 | 0.02 | -0.02 | -0 | -0 | 0 | Upgrade
|
| EBT Excluding Unusual Items | -5.93 | -6.2 | -6.15 | -5.75 | -1.75 | -0.67 | Upgrade
|
| Asset Writedown | - | - | -0.39 | - | - | - | Upgrade
|
| Legal Settlements | - | - | -0.21 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | 0.01 | 0.29 | - | - | Upgrade
|
| Pretax Income | -5.93 | -6.2 | -6.74 | -5.46 | -1.75 | -0.67 | Upgrade
|
| Income Tax Expense | -0.27 | -0.14 | - | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -5.65 | -6.07 | -6.74 | -5.46 | -1.75 | -0.67 | Upgrade
|
| Minority Interest in Earnings | 0.01 | 0.01 | 0.01 | 0 | 0.04 | 0.02 | Upgrade
|
| Net Income | -5.64 | -6.06 | -6.73 | -5.46 | -1.71 | -0.65 | Upgrade
|
| Net Income to Common | -5.64 | -6.06 | -6.73 | -5.46 | -1.71 | -0.65 | Upgrade
|
| Shares Outstanding (Basic) | 5 | 4 | 2 | 1 | 1 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 5 | 4 | 2 | 1 | 1 | 0 | Upgrade
|
| Shares Change (YoY) | 70.75% | 85.92% | 88.75% | 11.15% | 297.67% | 130.43% | Upgrade
|
| EPS (Basic) | -1.24 | -1.62 | -3.36 | -5.13 | -1.79 | -2.71 | Upgrade
|
| EPS (Diluted) | -1.24 | -1.62 | -3.36 | -5.13 | -1.79 | -2.71 | Upgrade
|
| Free Cash Flow | -5.9 | -5.17 | -7.2 | -4.18 | -0.81 | -0.59 | Upgrade
|
| Free Cash Flow Per Share | -1.29 | -1.39 | -3.59 | -3.93 | -0.85 | -2.45 | Upgrade
|
| Gross Margin | - | - | 32.34% | -15.94% | - | -7.62% | Upgrade
|
| Operating Margin | -196566.68% | -97344.76% | -3903.69% | -66963.68% | - | -520.54% | Upgrade
|
| Profit Margin | -189001.71% | -95739.17% | -4304.81% | -63748.32% | - | -525.75% | Upgrade
|
| Free Cash Flow Margin | -197677.16% | -81621.64% | -4602.71% | -48823.35% | - | -476.65% | Upgrade
|
| EBITDA | -5.56 | -5.91 | -6.05 | - | - | - | Upgrade
|
| D&A For EBITDA | 0.31 | 0.26 | 0.05 | - | - | - | Upgrade
|
| EBIT | -5.87 | -6.16 | -6.11 | -5.73 | -1.73 | -0.64 | Upgrade
|
| Revenue as Reported | - | - | - | - | - | 0.12 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.